Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond(University of Pennsylvania), Robert D. Schreiber(Parker Institute for Cancer Immunotherapy)
Cited by 1,040
Related Papers
Tumor neoantigens: building a framework for personalized cancer immunotherapy
|Journal of Clinical Investigation|2015|631
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas
|Breast Cancer Research|2012|198
Vav proteins control MyD88-dependent oxidative burst
|Blood|2006|83
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
|Blood Advances|2024|12
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
|Cancer Immunology Research|2024|6